Results 91 to 100 of about 3,014 (182)

Abstract B27: Improved survival with erdafitinib (JNJ-42756493) and PD-1 blockade mediated by enhancement of anti-tumor immunity in an FGFR2-driven genetically engineered mouse model of lung cancer

, 2017
Targeted therapies against activated oncogenes, such as receptor tyrosine kinases, have significantly prolonged non-small cell lung cancer (NSCLC) patient survival, but the development of resistance limits the durability of clinical response.
Wei Huang, Kwok-Kin Wong, Kristin Depeaux, Kathryn Packman, Sangeetha Palakurthi, Dennis Bonal, Sima Zacharek, Abha Dhaneshwar, Martha Gowaski, Mark Bittinger, Raluca I. Verona, Enrique Zudaire, Catherine Ferrante, Sylvie Laquerre, Kirschmeier Paul, Roderick Bronson, Jeff Liu, Matthew V. Lorenzi, Sam Regan, Dyane Bailey, Mei Zheng, Mari Kuraguchi   +21 more
core   +1 more source

Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants

Clinical Pharmacology in Drug Development
AbstractErdafitinib, a selective and potent oral pan‐FGFR inhibitor, is metabolized mainly through CYP2C9 and CYP3A4 enzymes. This phase 1, open‐label, single‐sequence, drug‐drug interaction study evaluated the pharmacokinetics, safety, and tolerability of a single oral dose of erdafitinib alone and when co‐administered with steady state oral ...
Pharavee, Jaiprasart, Peter, Hellemans, Juhui James, Jiao, Anne-Gaëlle, Dosne, Marc, De Meulder, Loeckie, De Zwart, Laurane, Brees, Wei, Zhu   +7 more
openaire   +2 more sources

Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial

BMC Cancer
Background FGFR genomic aberrations occur in approximately 5–10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecological, and other ...
Joon Oh Park, Yin-Hsun Feng, Wu-Chou Su, Do-Youn Oh, Bhumsuk Keam, Lin Shen, Sang-We Kim, Xiufeng Liu, Huimin Liao, Min Qing, Chong Zhang, Jiaqi Qian, Xiaodan Tang, Peng Li, Spyros Triantos, Hussein Sweiti   +15 more
doaj   +1 more source

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma

# Background For patients with locally advanced or metastatic urothelial carcinoma (la/mUC), prognosis is poor and effective treatment options are limited.
Simona Baculea, Zijiao Yuan, Suzy Van Sanden, Keith Stubbs, Ayman Youssef, Spyros Triantos, Caitlin Daly   +6 more
core   +1 more source

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies

Cancer Communications
In this review, we revisit the pivotal role of fibroblast growth factor receptor 3 (FGFR3) in bladder cancer (BLCA), underscoring its prevalence in both non‐muscle‐invasive and muscle‐invasive forms of the disease.
Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß‐Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, Martin Pichler   +7 more
doaj   +1 more source

Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models

Molecular Oncology
Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, most cases develop resistance to this therapy.
Ichiro Kawahara, Hirofumi Yoshino, Wataru Fukumoto, Junya Arima, Saeki Saito, Gang Li, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita, Masayuki Nakagawa, Shuichi Tatarano, Yasutoshi Yamada, Hideki Enokida   +14 more
doaj   +1 more source

FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression

The Journal of Clinical Investigation
The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) inhibition with ICI in urothelial carcinoma (UC) of the bladder, in which ...
Atsushi Okato, Takanobu Utsumi, Michela Ranieri, Xingnan Zheng, Mi Zhou, Luiza D. Pereira, Ting Chen, Yuki Kita, Di Wu, Hyesun Hyun, Hyojin Lee, Andrew S. Gdowski, John D. Raupp, Sean Clark-Garvey, Ujjawal Manocha, Alison Chafitz, Fiona Sherman, Janaye Stephens, Tracy L. Rose, Matthew I. Milowsky, Sara E. Wobker, Jonathan S. Serody, Jeffrey S. Damrauer, Kwok-Kin Wong, William Y. Kim   +24 more
doaj   +1 more source

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma. [PDF]

ESMO Open
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Nemat S, Gogate J, Li Q, Abdelgawad M, Siefker-Radtke AO.   +15 more
europepmc   +1 more source

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib

JAAD Case Reports, 2020
Alana Deutsch, BA, Beth N. McLellan, MD
doaj   +1 more source

Cost-Effectiveness of Erdafinib vs. Chemotherapy for Advanced or Metastatic Urothelial Carcinoma from the Payer Perspectives in the US and China

Background and objective: Erdafitinib is the first small-molecule fibroblast growth factor receptors (FGFRs) inhibitor targeting therapeutic approved by the FDA for advanced or metastatic urothelial carcinoma (mUC). However, due to the high cost of the
Qianxin Liu, Yijia Zhao, Bin Zhang, Zhiqi Zhang, Ying Zhou, Xiaocong Pang   +5 more
core   +1 more source